Business description
Operating under the "Zur Rose" and "DocMorris" brands, the Swiss-based Zur Rose Group is one of Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical practitioners. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management in order to increase therapy safety. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry. The Zur Rose Group serves the Swiss market from Frauenfeld, Switzerland. In Germany and Austria, the Group operates through subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany). Furthermore, it holds a majority interest in BlueCare in Winterthur, one of the leading providers of networking systems in the Swiss healthcare market.
Management board & Supervisory board
| CEO |
| Walter Hess |
| Management board |
| Marcel Ziwica, David Masó, Madhu Nutakki, Matthias Peuckert, Kaspar Niklaus |
| Supervisory board |
| Dr. Christian Mielsch, Florian Seubert, Prof. Dr. Andréa Belliger, Prof. Dr. Volker Amelung, Prof. Stefan Feuerstein, Walter Oberhänsli |
Company data
| Name: |
Zur Rose Group AG |
| Address: |
Walzmühlestrasse 60,CH-8500 Frauenfeld |
| Phone: |
+41-52-7240020 |
| Fax: |
+41-52-7240015 |
| E-mail: |
info@zurrose.com
|
| Internet: |
www.zurrosegroup.com |
| Industry: |
Consumer Goods |
| Sector: |
Retailers |
| Sub sector: |
- |
| End of financial year: |
12-31 |
| Free Float: |
75.60% |
| IPO date: |
2017-07-06 |
